$1.30 -0.08 (%) Amarin Corp Shs Sponsored American Deposit Receipt Repr 1 Sh - NASDAQ

Feb. 8, 2016 | 04:00 PM

Partner Headlines

  1. Amarin Announces Agreement to Purchase $16.2M of Its Existing Exchangeable Notes and Pricing of $31.3 Million of New Exchangeable Notes

    Benzinga | Nov. 20, 2015 | 06:04AM EST
  2. Amarin Popped Ahead Of Press Release In Friday's After-Hours Session

    Benzinga | Nov. 9, 2015 | 12:24PM EST
  3. Amarin Popped Amid Press Release In Friday's After-Hours Session

    Benzinga | Nov. 9, 2015 | 12:24PM EST
  4. EXCLUSIVE: Expect Amarin FAQ Shortly

    Benzinga | Nov. 9, 2015 | 11:14AM EST
  5. EPA Therapy Added to Statin Therapy Showed Coronary Plaque Regression at Approximately Twice the Prevalence Compared to Statin Therapy Alone in Japanese Clinical Study

    Benzinga | Nov. 9, 2015 | 08:09AM EST
  6. UPDATE: WHat Amarin Would Need TO Disclose To Ensure Non-Misleading Speech

    Benzinga | Aug. 7, 2015 | 10:56AM EST
  7. First Amendment Decision a Win for Amarin and Physician Plaintiffs

    Benzinga | Aug. 7, 2015 | 10:52AM EST
  8. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

    Benzinga | Jan. 13, 2015 | 11:34AM EST
  9. Week Concludes With S&P 500 Below 2,000; Dow Below 17,000

    Benzinga | Sep. 12, 2014 | 16:51PM EST
  10. Dow Falls Over 100 Points; Ulta Salon Shares Jump After Earnings Report

    Benzinga | Sep. 12, 2014 | 15:59PM EST
  11. Conversant Shares Rise On Acquisition News; Health Care REIT Drops

    Benzinga | Sep. 12, 2014 | 14:02PM EST
  12. Markets Drop; Darden Adjusted Profit Beats Street View

    Benzinga | Sep. 12, 2014 | 11:26AM EST
  13. Morning Market Losers

    Benzinga | Sep. 12, 2014 | 09:45AM EST
  14. Amarin Moves Higher On Speculation Of Special Protocol Assessment

    Benzinga | Jul. 31, 2014 | 12:01PM EST
  15. Top Performing Industries For June 12, 2014

    Benzinga | Jun. 12, 2014 | 10:28AM EST
  16. FDA Approvals And Changes For The Week Ending February 14, 2014

    Benzinga | Feb. 18, 2014 | 16:17PM EST
  17. Amarin Announces FDA DMEP Does Not Plan to Re-instate ANCHOR SPA Agreement

    Benzinga | Jan. 21, 2014 | 05:46AM EST
  18. Benzinga's Top #PreMarket Losers

    Benzinga | Jan. 16, 2014 | 08:22AM EST
  19. Amarin Announces FDA Review Division Response on ANCHOR SPA Agreement Reinstatement Request Will Be Delayed

    Benzinga | Jan. 15, 2014 | 16:05PM EST
  20. FDA Delays Decision on Amarin's Vascepa Drug

    Benzinga | Dec. 20, 2013 | 12:46PM EST
  21. Amarin Receives FDA Notification That Action on ANCHOR sNDA Review Will be Delayed

    Benzinga | Dec. 20, 2013 | 06:03AM EST
  22. Amarin's Vascepa: Too Limited A Market Or FDA Blunder?

    Benzinga | Dec. 18, 2013 | 14:11PM EST
  23. Amarin Announces Notification of Patent Allowances Related to Triglyceride Lowering With a Mixture of Omega-3 Free Fatty Acid (Including EPA and/or DHA) in Both the MARINE and ANCHOR Patient Populations

    Benzinga | Dec. 2, 2013 | 06:05AM EST
  24. New Statin Rules: Which Drugmakers Had Ties?

    YCharts | Nov. 14, 2013 | 19:39PM EST
  25. Is Amarin’s Fish Oil Blockbuster Dream Kaput?

    YCharts | Nov. 9, 2013 | 03:03AM EST
  26. UPDATE: Citigroup Upgrades Amarin on Valuation

    Benzinga | Nov. 8, 2013 | 09:31AM EST
  27. Benzinga's Top Upgrades

    Benzinga | Nov. 8, 2013 | 07:29AM EST
  28. Aegis Capital Corp. Reiterates on Amarin Corporation plc After FDA Formally Rescinds Special Protocol Assessment

    Benzinga | Oct. 30, 2013 | 11:00AM EST
  29. Market Wrap For Thursday, October 17: S&P Record High On Debt Deal

    Benzinga | Oct. 17, 2013 | 16:41PM EST
  30. Mid-Day Market Update: SanDisk Surges On Upbeat Results; IBM Shares Tumble

    Benzinga | Oct. 17, 2013 | 12:59PM EST
  31. Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Revenue Drops 20%

    Benzinga | Oct. 17, 2013 | 11:10AM EST
  32. Stocks Hitting 52-Week Lows

    Benzinga | Oct. 17, 2013 | 10:10AM EST
  33. UPDATE: Aegis Capital Downgrades Amarin Following Negative Panel Vote on Vascepa

    Benzinga | Oct. 17, 2013 | 09:14AM EST
  34. Benzinga's Top Pre-Market Losers

    Benzinga | Oct. 17, 2013 | 08:16AM EST
  35. Amarin Announces Negative FDA Advisory Committee Outcome for the Use of Vascepa in the Treatment of High Triglycerides With Mixed Dyslipidemia

    Benzinga | Oct. 16, 2013 | 16:20PM EST
  36. Amarin Halted Ahead of FDA Advisory Committee to Review sNDA for Vascepa( ANCHOR Indication

    Benzinga | Oct. 16, 2013 | 05:56AM EST
  37. Aegis Says FDA's Outlook 'Not As Negative As People Think' on Amarin

    Benzinga | Oct. 14, 2013 | 13:30PM EST
  38. Aegis Capital Reiterates Buy on Amarin Corporation Following Release of Vascepa Briefing Documents

    Benzinga | Oct. 14, 2013 | 10:47AM EST
  39. Jefferies Reiterates Buy on Amarin Corporation on Continued Positive Outlook

    Benzinga | Oct. 10, 2013 | 12:20PM EST
  40. Goldman Sachs Reiterates Neutral on Amarin Ahead of Advisory Panel

    Benzinga | Oct. 9, 2013 | 11:26AM EST
  41. Amarin Shares Up 5% as FDA Says October 16th Advisory Committee Meeting Will Take Place as Scheduled

    Benzinga | Oct. 3, 2013 | 08:56AM EST
  42. Enrollment in Amarin REDUCE-IT Cardiovascular Outcomes Study Surpasses 6,000 Patients

    Benzinga | Sep. 25, 2013 | 06:33AM EST
  43. Amarin Reports 30th Patent for Vascepa

    Benzinga | Sep. 9, 2013 | 07:20AM EST
  44. Amarin Submits Supplemental NDA for Novasep as Fourth Vascepa Active Pharmaceutical Ingredient Supplier

    Benzinga | Aug. 26, 2013 | 06:02AM EST
  45. UPDATE: Citigroup Raises PT on Amarin Following Lighter 2Q13 Sales

    Benzinga | Aug. 12, 2013 | 08:36AM EST
  46. UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership Discussion

    Benzinga | Aug. 9, 2013 | 12:33PM EST
  47. Amarin Announces USPTO Allowance for Application 13/614,129 Related to Vascepa and FDA Approved MARINE Indication

    Benzinga | Feb. 11, 2013 | 23:02PM EST
  48. Amarin Announces Patent Allowance Related to Vascepa and FDA Approved MARINE Indication

    Benzinga | Jan. 11, 2013 | 00:33AM EST
  49. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus | Jan. 7, 2013 | 04:34AM EST
  50. Benzinga's Top Pre-Market Gainers

    Benzinga | Jan. 7, 2013 | 01:12AM EST
Trading Center